Related Experiment Videos
App-Based Digital Therapeutics Integrating Continuous Glucose Monitoring for Glycemic Control in Type 2 Diabetes:
Banshi Saboo1, Mudit Sabharwal2, Mihir Gharia3
1Diabetes Care and Hormone Clinic, Dia Care Research, Ahmedabad, Gujarat, India.
JMIR Diabetes
|July 8, 2026
Summary
Digital therapeutics combining continuous glucose monitoring (CGM) and lifestyle coaching improve glycemic control in type 2 diabetes mellitus (T2DM). This app-based intervention showed clinically meaningful benefits in glycemic control and quality of life.
Area of Science:
- Digital Health
- Metabolic Diseases
- Behavioral Medicine
Background:
- Digital therapeutics integrating continuous glucose monitoring (CGM) and personalized coaching can improve glycemic control in type 2 diabetes mellitus (T2DM).
- Real-world evidence for multicomponent digital interventions combining CGM, nutrition, physiotherapy, and cognitive behavioral therapy is limited in South Asian populations.
Purpose of the Study:
- To evaluate the effectiveness of the app-based GLIDE-C (Glycemic Lifestyle Intervention in Diabetes Empowerment-CGM) program.
- Assessed impact on glycemic, anthropometric, lipid profile, quality of life (QoL), and behavioral outcomes in adults with T2DM.
- Explored health economics and outcomes research (HEOR) related outcomes.
Main Methods:
- Prospective observational cohort study of adults (≥18 years) with T2DM and HbA1c 7.5%-9.5%.
- Intervention delivered via the Goodflip mobile app, including a 15-day CGM period, glucose variation analysis, and follow-up at 15, 30, and 60 days.
- Combined CGM-guided personalized diet, exercise, and cognitive behavioral therapy plans with multidisciplinary coaching.
Main Results:
- Mean HbA1c decreased by 0.59% (P=.05); postprandial glucose decreased by 25.42 mg/dL (P=.06).
- Time in range increased by 9.98%; modest reductions observed in LDL cholesterol, body fat, and waist circumference.
- Significant QoL improvement in sleep quality (P=.04); motivation, stress management, and mood showed non-significant improvements.
Conclusions:
- The GLIDE-C program demonstrated clinically meaningful improvements in glycemic control, behavioral outcomes, and QoL in T2DM patients without pharmacological changes.
- Integrated, CGM-guided digital therapeutic platforms serve as effective adjuncts to conventional care.
- Behavioral analysis highlighted strong associations between reduced intake of energy-dense, nutrient-poor foods and improved glycemic outcomes.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...